Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Immune Response to FMT for C.Difficile

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by University of Virginia
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
William Petri, MD, University of Virginia
ClinicalTrials.gov Identifier:
NCT02797288
First received: May 27, 2016
Last updated: February 12, 2017
Last verified: February 2017
  Purpose
The protocol aims to address the basic mechanisms of Clostridium difficile pathogenesis by identifying how Clostridium difficile toxins inhibit eosinophils that otherwise would protect the gut from damage. This could lead to new and effective approaches to the treatment or prevention of Clostridium difficile colitis that act downstream of fecal microbiota transplants (FMT) or next generation probiotics. Successful fecal transplantation will restore Interleukin-25, Interleukin-4 and eosinophils to the colon

Condition
Clostridium Difficile

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Role of Eosinophils in Innate Protection From C. Difficile

Further study details as provided by University of Virginia:

Primary Outcome Measures:
  • tissue IL-25 [ Time Frame: 0-60 days post fecal transplant ]

Secondary Outcome Measures:
  • Tissue IL-4 [ Time Frame: 0-60 days post fecal transplant ]
  • Tissue IL-1 [ Time Frame: 0-60 days post fecal transplant ]
  • Tissue histology [ Time Frame: 0-60 days post fecal transplant ]
  • Tissue 16s rDNA [ Time Frame: 0-60 days post fecal transplant ]
  • Plasma metabolomics [ Time Frame: 0-60 days post fecal transplant ]
  • Tissue eosinophils [ Time Frame: 0-60 days post fecal transplant ]
    single-cell atomic mass spectrometry


Biospecimen Retention:   Samples With DNA
Colon biopsies

Estimated Enrollment: 10
Study Start Date: July 2016
Estimated Study Completion Date: March 2021
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Detailed Description:
Biopsies will be obtained from random areas of the sigmoid colon in subjects at the time of fecal transplantation. Follow-up biopsies will be obtained from the sigmoid colon during convalescence 60 days after fecal transplant for subjects who agree to return for optional 60 day follow-up. Biopsies taken for research purposes at each colonoscopy will be analyzed for: cytokines and chemokines, gene expression analysis, immunohistochemistry and high dimensional flow-cytometry.
  Eligibility

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients receiving fecal transplant for recurrent Clostridium difficile infection identified from the University of Virginia complicated Clostridium difficile clinic
Criteria

Inclusion Criteria:

  • one or more relapse of Clostridium difficile colitis
  • eligible for fecal microbiota transplant

Exclusion Criteria:

  • Unwilling to have biopsies for research conducted at time of FMT
  • Concurrent participation in another clinical trial, except outcome of FMT study
  • Clinical contraindication to colonoscopy, FMT, flexible sigmoidoscopy or conscious sedation
  • Pregnancy
  • Inability to give informed consent
  • Incarceration
  • Antibiotics unless discontinued 48 hours prior to FMT
  • Celiac disease or any other form of inflammatory bowel disease
  • HIV infection
  • Neutropenia (<1000 PMNs/µl blood)
  • Concurrent participation in another clinical trial, except outcome of FMT study
  • Anticoagulants if not able to discontinue 5 days prior to endoscopy and flexible sigmoidoscopy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02797288

Contacts
Contact: William A. Petri, MD,PhD 434-924-5621 wap3g@virginia.edu
Contact: Jennifer White, BSN 434-982-3649 jaw9r@virginia.edu

Locations
United States, Virginia
University of Virginia Health System Recruiting
Charlottesville, Virginia, United States, 22903
Contact: William A. Petri, MD,PhD    434-924-5621    wap3g@virginia.edu   
Sponsors and Collaborators
University of Virginia
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Principal Investigator: William A. Petri, MD,PhD University of Virginia
  More Information

Responsible Party: William Petri, MD, Chief, Infectious Diseases & International Health, University of Virginia
ClinicalTrials.gov Identifier: NCT02797288     History of Changes
Other Study ID Numbers: 18782
R01AI124214-01 ( US NIH Grant/Contract Award Number )
Study First Received: May 27, 2016
Last Updated: February 12, 2017
Individual Participant Data  
Plan to Share IPD: No

ClinicalTrials.gov processed this record on May 25, 2017